Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 2, 2011, Pages 255-260

  Chrusciak Talhari, Anette ^a   Dietze, Reynaldo ^b   Talhari, Carolina Chrusciak ^a   Da Silva, Roberto Moreira ^a   Yamashita, Ellen Priscila Gadelha ^a   De Oliveira Penna, Gerson ^c   Machado, Paulo Roberto Lima ^d   Talhari, Sinésio ^a  

^a FUNDAÇÃO DE MEDICINA TROPICAL DR HEITOR VIEIRA DOURADO   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PENTAMIDINE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND; PHOSPHORYLCHOLINE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAZIL; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HUMAN; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; ORCHITIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCROTAL SWELLING; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIA GUYANENSIS;

ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIA GUYANENSIS; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952641526     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0155     Document Type: Article

References (19)

1. Grimaldi G Jr, Momen H, Naiff RD, McMahon-Pratt D, 1991. Characterization and classification of leishmanial parasites from humans, wild mammals, and sand flies in the Amazon region of Brazil. Am J Trop Med Hyg 44: 645-661.
2. Lainson R, Shaw JJ, Silveira FT, de Souza AA, Braga RR, Ishikawa EA, 1994. The dermal leishmaniases of Brazil, with special reference to the ecoepidemiology of the disease in Amazonia. Mem Inst Oswaldo Cruz 89: 435-443.
3. Ministério da Saúde, Fundação Nacional de Saúde, Centro Nacional de Epidemiologia, (Brazil), 2007. Manual de Vigilância da Leishmaniose Tegumentar Americana. Second edition. Brasília: Ministério da Saúde. Available at: http://portal.saude .gov.br/portal/arquivos/pdf/manual-lta-2ed.pdf. Accessed May 11, 2010.
4. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M, 2006. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S26-S33. (Pubitemid 44490165)
5. Soto J, Berman J, 2006. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 (Suppl 1): S34-40. (Pubitemid 44490170)
6. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman JD, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: 57-61.
7. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272. (Pubitemid 38608569)
8. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman JD, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infec Dis 44: 350-356. (Pubitemid 46147616)
9. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210-211.
10. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda- Verástegui C, Lazo M, Loayza-Muro R, De Doncker S, Maurer A, Chappuis F, Dujardin JC, Llanos-Cuentas A, 2007. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 1846-1851. (Pubitemid 46870258)
11. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J, Dujardin JC, Arevalo J, Chappuis F, 2008. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 46: 223-231. (Pubitemid 351269161)
12. Saldanha AC, Romero GA, Merchan-Hamann E, Magalhães VA, Macedo VO, 1999. Comparative study between sodium stibogluconate BP 88 and meglumina antimoniate for cutaneous leishmaniasis treatment: I. Efficacy and safety. Rev Soc Bras Med Trop 32: 383-387. (Pubitemid 29441382)
13. Deps PD, Viana MC, Falqueto A, Dietze R, 2000. Evaluation of the efficacy and toxicity of N-methyl-glucamine vs. BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev Soc Bras Med Trop 33: 535-543. (Pubitemid 32108388)
14. Romero GA, Guerra MV, Paes MG, Macedo VO, 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65: 456-465. (Pubitemid 33134577)
15. Garcia L, Kindt A, Bermudez H, Llanos-Cuentas A, De Doncker S, Arevalo J, Tintaya KW, Dujardin JC, 2004. Cultureindependent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 42: 2294-2297. (Pubitemid 38637869)
16. Berman J, 2003. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16: 397-401. (Pubitemid 37267258)
17. Rotureau B, Ravel C, Nacher M, Couppie P, Curtet I, Dedet JP, Carme B, 2006. Molecular epidemiology of Leishmania (Viannia) guyanensis in French Guiana. J Clin Microbiol 44: 468-473. (Pubitemid 43222239)
18. Romero GA, Ishikawa E, Cupolillo E, Toaldo CB, Guerra MV, Paes MG, Macedo VO, Shaw JJ, 2002. Identification of antigenically distinct populations of Leishmania (Viannia) guyanensis from Manaus, Brazil, using monoclonal antibodies. Acta Trop 82: 25-29. (Pubitemid 34246256)
19. McMahon-Pratt D, Bennett E, David JR, 1982. Monoclonal antibodies that distinguish subspecies of Leishmania braziliensis. J Immunol 129: 926-927. (Pubitemid 12055544)